MEDIPOST disclosed on 10 July that they obtained patent from the Japanese Patent Office in relation to ‘Composition for treatment of articular cartilage damage’ which is the main technology of formulation of cartilage regeneration drug ‘CARTISTEM^®’

This patented technology is regarding cartilage damage treatment containing cord blood originated stem cell component, and culture medium and human body suitability macromolecule, and will be utilized in the process of administering ‘CARTISTEM^®’ to arthritis patients. With this patent, MEDIPOST secured the exclusive right in Japan in relation to ‘CARTISTEM^®’ treatment, and became able to actively take part in sales contracts and obtaining item approval in Japan in the future.

MEDIPOST is currently discussing with the Japanese health authorities and medical personnel in order to obtain item approval of ‘CARTISTEM^®’ with minimal clinical trial stage.